GTx Announces Presentation of Ostarine and Acapodene Data at 2007 ASCO Annual Meeting
MEMPHIS, Tenn.--(BUSINESS WIRE)--May 25, 2007 - GTx, Inc., (NASDAQ: GTXI) announced today that data from the recent Phase II proof of concept clinical trial of Ostarine(TM) and from the ongoing Phase III clinical trial evaluating ACAPODENE(R) (toremifene citrate) 80 mg for the treatment of multiple...Ostarine - Wikipedia, the free encyclopedia
Ostarine is an investigational selective androgen receptor modulator (SARM) developed by GTx Inc for treatment of conditions such as muscle wasting and osteoporosis. Treatment with exogenous testosterone is effective in counteracting these symptoms but is associated...GTx, Inc. Initiates Phase II Clinical Trial Of Ostarine, A First-in ...
the Men's Health Biotech Company, announced today that it hasinitiated a proof of concept Phase II clinical trial of ostarine, afirst-in-class drug. The clinical ...Ostarine Profile SARMS Selective Androgen Receptor Modulators
Ostarine - SARMs Profile (a/k/a/ SARM-4, S-4) Family: ... Ostarine by GTx Inc. ... GTx Announces That Ostarine Achieved Primary Endpoint Of Lean Body Mass And A ...GTx. Ostarine™ (MK-2866): Aiming to Build Muscle in the Elderly and in ...
GTx and collaboration partner Merck & Co. are evaluating Ostarine™ (also designated by Merck as MK-2866) and other selective androgen receptor modulators, or SARMs, ...GTx Initiates Phase IIb Ostarine Clinical Trial for Cancer Cachexia
GTx announced  that it has initiated a Phase IIb clinical trial evaluating Ostarine for the treatment of cancer cachexia.Ostarine, new steroid without side effects
Ostarine, a SARM, is being developed to treat a variety of medical conditions ... Ostarine is a novel non-steroidal agent designed to have anabolic activity like ...